section name header

Basics

Outline


BASICS

Overview!!navigator!!

  • BAs are cholesterol derivatives made by the liver and secreted via the biliary tree into the small intestine, where they emulsify dietary lipid and enhance its digestion by pancreatic lipases
  • Primary functions of BAs:
    • Facilitate cholesterol excretion
    • Stimulate hepatic bile flow
    • Enhance dietary lipid absorption
  • During digestion, primary BAs are dehydroxylated by enteric bacteria to secondary BAs
  • BAs are reabsorbed from the gastrointestinal tract in the ileum; they are transported back to the liver via portal circulation, where they are extracted by the liver, conjugated, and resecreted. Approximately 90% of the BA pool is concentrated in the enterohepatic circulation, and may be recycled 10–40 times/day
  • Under physiologic conditions, equilibrium exists between intestinal absorption, hepatic uptake from the portal circulation, and hepatic secretion of BAs; this is represented and quantified as the SBAs
  • Assessment of SBAs in the horse can be performed at any time, as the horse does not store BAs in a gallbladder between meals. Further, SBA concentrations do not display diurnal variation in this species
  • Reference range < 12 μmol/L
  • Elevated SBA concentration is a sensitive and specific marker of hepatic disease; however, the nature of the lesion cannot be determined by this parameter alone
  • The primary BAs are taurocholic, taurochenodeoxycholic, and glycochenodeoxycholic acid; the majority of BAs are conjugated with taurine. Conjugation is required for secretion
  • Three general mechanisms increase SBAs:
    • Failure of hepatocytes to extract BAs from portal blood
    • Biliary stasis
    • Portosystemic shunting

Signalment!!navigator!!

Any breed, age, or sex.

Signs!!navigator!!

  • BA accumulation in the skin has been suggested to induce pruritus
  • Signs of hepatic dysfunction
    • Icterus
    • Anorexia, weight loss
    • Depression
    • Edema
    • Hepatic encephalopathy
    • Photosensitization
    • Colic
    • Diarrhea
    • Hemolysis (rare, but significant)
    • Hemorrhagic diathesis (rare)

Causes and Risk Factors!!navigator!!

  • Acute disease
    • Theiler's disease
    • Hepatic lipidosis
    • Tyzzer's disease
    • Cholangiohepatitis
    • Biliary obstruction
      • Cholelithiasis/choledocholithiasis
      • Colon displacement
  • Parasitic hepatitis
  • Toxic hepatopathy (iron, drugs, plants, mycotoxins)
  • Viral hepatitis (equine infectious anemia, equine viral arteritis, equine herpesvirus 1)
  • Chronic disease
    • Pyrrolizidine alkaloid toxicity
    • Chronic active hepatitis
    • Cholelithiasis
    • Neoplasia
    • Hepatic abscess
  • Congenital disease
    • Portosystemic shunt

Diagnosis

Outline


DIAGNOSIS

CBC/Biochemistry/Urinalysis!!navigator!!

  • CBC—may suggest inflammation (leukocytosis, neutrophilia) or anemia of chronic disease
  • Biochemistry—increased γ-glutamyltransferase, aspartate aminotransferase, sorbitol dehydrogenase, alkaline phosphatase, bilirubin; decreased albumin, blood urea nitrogen, glucose

Other Laboratory Tests!!navigator!!

  • Blood ammonia concentration
  • Plasma fibrinogen concentration

Imaging!!navigator!!

  • Hepatic ultrasonography
    • Hyperechogenicity noted in cases of hepatic fibrosis, hepatic lipidosis
    • Nodules
    • Biliary dilatation
    • Choleliths
    • Hepatomegaly

Other Diagnostic Procedures!!navigator!!

  • Biopsy to characterize hepatic lesions and formulate prognosis (acute hepatitis vs. hepatic fibrosis)
  • Coagulation profile prior to collecting biopsy, but coagulopathy does not predict risk of biopsy complication

Treatment

TREATMENT

  • Treatment of underlying cause
  • Supportive care, as initial inciting insult may no longer be present (e.g. pyrrolizidine alkaloid hepatotoxicity)
  • Low-protein, highly soluble carbohydrate diet with low aromatic amino acid to branched-chain amino acid ratio

Medications

Outline


MEDICATIONS

Drug(s) of Choice!!navigator!!

Dependent on the underlying cause.

Contraindications/Possible Interactions!!navigator!!

Dependent on the underlying cause.

Follow-up

Outline


FOLLOW-UP

Patient Monitoring!!navigator!!

Serial monitoring of biochemistry and SBAs.

Prevention/Avoidance!!navigator!!

  • Use caution in the administration of equine-origin biologics (e.g. plasma, tetanus anti-toxin) to adult horses
  • Avoid exposure to hepatotoxic plants and medications

Possible Complications!!navigator!!

  • Coagulopathy and hemorrhagic diathesis with severe hepatic failure
  • Self-trauma in patients with hepatic encephalopathy

Expected Course and Prognosis!!navigator!!

  • Dependent on the underlying cause, but most etiologies carry a prognosis that is guarded to poor
  • SBA concentration >50 μmol/L has been associated with a poor prognosis in horses with pyrrolizidine alkaloid toxicosis, and SBA concentration >20 μmol/L has been associated with nonsurvival (short and long term) in equine liver disease

Miscellaneous

Outline


MISCELLANEOUS

Age-Related Factors!!navigator!!

The SBA concentration of neonatal foals is substantially higher than that observed in adult horses.

Abbreviations!!navigator!!

  • BA = bile acid
  • SBA = serum bile acid

Suggested Reading

Dunkel B, Jones SA, Pinilla MJ, Foote AK. Serum bile acid concentrations, histopathological features, and short- and long-term survival in horses with hepatic disease.J Vet Intern Med 2015;29(2):644650.

Author(s)

Author: Teresa A. Burns

Consulting Editor: Sandra D. Taylor

Additional Further Reading

Click here for Additional Further Reading